Pseudomonas Aeruginosa Infection
📧 Sign up to get email alerts when something new happens for Pseudomonas Aeruginosa Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-05-25Clinical Trial Update: Targeted AntiBiotics for Chronic Pulmonary Diseases [Phase 4]
Phase 4 clinical trial update for targeted antibiotics in chronic pulmonary diseases has been terminated.
-
FDA approval · 2021-07-13FDA Approved: TOBRAMYCIN — Supplemental Application (Gland Pharma Limited)
FDA approved a supplemental application for Tobramycin filed by Gland Pharma Limited.
-
CLINICAL_TRIALS trial_result · 2021-06-02Clinical Trial Update: Open Label Extension to Bridging Study CTBM100C2303 [Phase 3]
Open-label extension to a bridging Phase 3 study for Pseudomonas aeruginosa and cystic fibrosis was completed with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2019-07-26Clinical Trial Update: Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection [Phase 3]
Phase 3 extension study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection compl…
-
CLINICAL_TRIALS trial_result · 2019-06-24Clinical Trial Update: Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections [Phase 3]
A Phase 3 study evaluating Arikayce in cystic fibrosis patients with chronic Pseudomonas aeruginosa infections has completed with results po…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-04-13Clinical Trial Update: Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients [Phase 4]
Phase 4 trial evaluating population pharmacokinetics and safety of intravenous ceftolozane/tazobactam in adult cystic fibrosis patients, com…
-
CLINICAL_TRIALS trial_result · 2017-02-24Clinical Trial Update: Pharmacokinetic Evaluation of an 8 -Week Treatment With Inhaled Tobramycin [Phase 3]
Phase 3 trial update reporting pharmacokinetic evaluation of an 8-week course of inhaled tobramycin for Pseudomonas aeruginosa infections.
-
CLINICAL_TRIALS trial_result · 2016-09-01Clinical Trial Update: Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial evaluating anti-pseudomonas IgY to prevent infections in cystic fibrosis patients.
-
CLINICAL_TRIALS trial_result · 2016-03-31Clinical Trial Update: Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 [Phase 2, Phase 3]
A confirmatory Phase II/III trial evaluating the IC43 vaccine for Pseudomonas aeruginosa infection has completed.
-
CLINICAL_TRIALS trial_result · 2015-11-06Clinical Trial Update: A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies
Completed clinical trial comparing microbiological resistance and effects when alternating inhaled antibiotic therapies in cystic fibrosis p…
-
FDA approval · 2015-09-11FDA Approved: TOBI PODHALER — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for TOBI Podhaler (tobramycin) by Viatris Specialty LLC to update the product labeling.
-
CLINICAL_TRIALS research · 2015-07-24Clinical Trial Update: Evaluation of Phage Therapy for the Treatment of Escherichia Coli and Pseudomonas Aeruginosa Wound Infections in Burned Patients [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial update evaluating Phagenix's bacteriophage therapy for wound infections caused by Escherichia coli and Pseu…
-
CLINICAL_TRIALS trial_result · 2015-03-27Clinical Trial Update: Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children [Phase 4]
Phase 4 clinical trial update reports population pharmacokinetics of prolonged-infusion meropenem in children with cystic fibrosis. The stud…
-
FDA approval · 2014-12-02FDA Approved: TOBRAMYCIN INHALATION SOLUTION PAK — Original Application (Genericus, Inc.)
FDA approved Genericus, Inc.'s Tobramycin Inhalation Solution Pak, a generic version of tobramycin inhalation solution for patients with cys…
-
CLINICAL_TRIALS trial_result · 2014-09-22Clinical Trial Update: Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa [Phase 3]
This document provides an update on a Phase 3 clinical trial comparing continuous versus intermittent infusion of Zosyn (piperacillin-tazoba…
-
FDA approval · 2014-07-09FDA Approved: CAYSTON — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for Cayston (aztreonam) submitted by Gilead Sciences, Inc.
-
CLINICAL_TRIALS trial_result · 2014-05-01Clinical Trial Update: Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways [Phase 3]
Phase 3 safety results for AZLI in children with cystic fibrosis and chronic Pseudomonas aeruginosa infection have been posted. The trial is…
-
CLINICAL_TRIALS trial_result · 2013-11-21Clinical Trial Update: Cipro Inhaler for Cystic Fibrosis Children Ages 6-12 [Phase 1]
A Phase 1 clinical trial evaluating inhaled ciprofloxacin (Cipro Inhaler) in children with cystic fibrosis has completed.
-
FDA approval · 2013-03-22FDA Approved: TOBI PODHALER — Original Application (Viatris Specialty LLC)
FDA approved TOBI PODHALER (tobramycin inhalation powder) via an Original Application submitted by Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2013-03-21Clinical Trial Update: Sino-nasal Inhalation of Colistin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization [Phase 2]
Phase 2 trial evaluating sino-nasal inhaled colistin in cystic fibrosis patients with Pseudomonas aeruginosa colonization has completed.
-
CLINICAL_TRIALS approval · 2012-12-13Clinical Trial Update: Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis
Expanded access program update for aztreonam lysine inhalation (Cayston) in Canadian cystic fibrosis patients, noting marketing approval sta…
-
CLINICAL_TRIALS research · 2012-01-02Clinical Trial Update: Colistin Plus Rifampicin in MDR P. Aeruginosa and A. Baumanii [Phase 3]
Phase 3 clinical trial update evaluating the combination of colistin and rifampicin for infections caused by Pseudomonas aeruginosa and Acin…
-
FDA approval · 2010-02-22FDA Approved: CAYSTON — Original Application (Gilead Sciences, Inc.)
The FDA granted original approval to Cayston (aztreonam for inhalation solution) from Gilead for the treatment of cystic fibrosis patients c…
-
CLINICAL_TRIALS trial_result · 2010-01-26Clinical Trial Update: Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection [Phase 2]
A Phase 2 clinical trial evaluating aztreonam for inhalation in cystic fibrosis patients with Pseudomonas aeruginosa infection has completed…
-
CLINICAL_TRIALS trial_result · 2009-07-31Clinical Trial Update: Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa [Phase 1, Phase 2]
A Phase 1/2 pilot trial of KB001 in mechanically ventilated patients colonized with Pseudomonas aeruginosa has completed.